
Sean Mcgarry
Examiner (ID: 19573, Phone: (571)272-0761 , Office: P/1674 )
| Most Active Art Unit | 1635 |
| Art Unit(s) | 1635, 1809, 1805, 1674, 1621, 1624 |
| Total Applications | 1922 |
| Issued Applications | 1098 |
| Pending Applications | 296 |
| Abandoned Applications | 560 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 14881541
[patent_doc_number] => 10420789
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-09-24
[patent_title] => Methods and compositions for the activation of gamma-delta T-cells
[patent_app_type] => utility
[patent_app_number] => 16/132247
[patent_app_country] => US
[patent_app_date] => 2018-09-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 25630
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16132247
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/132247 | Methods and compositions for the activation of gamma-delta T-cells | Sep 13, 2018 | Issued |
Array
(
[id] => 16298050
[patent_doc_number] => 20200283773
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-10
[patent_title] => NUCLEOLIN-TARGETING APTAMERS AND METHODS OF USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 16/645762
[patent_app_country] => US
[patent_app_date] => 2018-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9249
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16645762
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/645762 | Nucleolin-targeting aptamers and methods of using the same | Sep 9, 2018 | Issued |
Array
(
[id] => 16941271
[patent_doc_number] => 11053500
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-07-06
[patent_title] => Modulation of prekallikrein (PKK) expression
[patent_app_type] => utility
[patent_app_number] => 16/125159
[patent_app_country] => US
[patent_app_date] => 2018-09-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 66328
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 110
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16125159
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/125159 | Modulation of prekallikrein (PKK) expression | Sep 6, 2018 | Issued |
Array
(
[id] => 16053139
[patent_doc_number] => 20200188424
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-18
[patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES
[patent_app_type] => utility
[patent_app_number] => 16/642393
[patent_app_country] => US
[patent_app_date] => 2018-08-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15307
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16642393
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/642393 | Compositions and methods for the treatment of fibrotic diseases | Aug 29, 2018 | Issued |
Array
(
[id] => 16613967
[patent_doc_number] => 20210032620
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-04
[patent_title] => OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/636902
[patent_app_country] => US
[patent_app_date] => 2018-08-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 170867
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16636902
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/636902 | Oligonucleotide compositions and methods thereof | Aug 6, 2018 | Issued |
Array
(
[id] => 16452911
[patent_doc_number] => 20200362337
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-19
[patent_title] => OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/636900
[patent_app_country] => US
[patent_app_date] => 2018-08-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 139374
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -51
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16636900
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/636900 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Aug 6, 2018 | Abandoned |
Array
(
[id] => 16720410
[patent_doc_number] => 20210087557
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-25
[patent_title] => METHODS AND COMPOSITIONS FOR TARGETED GENOMIC INSERTION
[patent_app_type] => utility
[patent_app_number] => 16/634215
[patent_app_country] => US
[patent_app_date] => 2018-07-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25269
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16634215
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/634215 | Methods and compositions for targeted genomic insertion | Jul 25, 2018 | Issued |
Array
(
[id] => 13827137
[patent_doc_number] => 20190017053
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-17
[patent_title] => TREATMENT USING TRUNCATED TRK B AND TRK C ANTAGONISTS
[patent_app_type] => utility
[patent_app_number] => 16/041638
[patent_app_country] => US
[patent_app_date] => 2018-07-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33831
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16041638
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/041638 | Treatment using truncated Trk B and Trk C antagonists | Jul 19, 2018 | Issued |
Array
(
[id] => 15931799
[patent_doc_number] => 20200157533
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-21
[patent_title] => META-STABLE OLIGONUCLEOTIDES JUNCTIONS FOR DELIVERY OF THERAPEUTICS
[patent_app_type] => utility
[patent_app_number] => 16/631134
[patent_app_country] => US
[patent_app_date] => 2018-07-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9609
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16631134
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/631134 | Meta-stable oligonucleotides junctions for delivery of therapeutics | Jul 13, 2018 | Issued |
Array
(
[id] => 15832467
[patent_doc_number] => 20200131515
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-30
[patent_title] => APTAMERS FOR MEASURING LIPOPROTEIN LEVELS
[patent_app_type] => utility
[patent_app_number] => 16/629223
[patent_app_country] => US
[patent_app_date] => 2018-07-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8179
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -51
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16629223
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/629223 | Aptamers for measuring lipoprotein levels | Jul 5, 2018 | Issued |
Array
(
[id] => 13774907
[patent_doc_number] => 20190000992
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-03
[patent_title] => Piggyback Delivery of CRISPR/CAS9 RNA into Zebrafish Blood Cells
[patent_app_type] => utility
[patent_app_number] => 16/023753
[patent_app_country] => US
[patent_app_date] => 2018-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5363
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 77
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16023753
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/023753 | Piggyback Delivery of CRISPR/CAS9 RNA into Zebrafish Blood Cells | Jun 28, 2018 | Abandoned |
Array
(
[id] => 13942303
[patent_doc_number] => 10206896
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-02-19
[patent_title] => Method of treating delayed healing of a wound associated with diabetes
[patent_app_type] => utility
[patent_app_number] => 16/020517
[patent_app_country] => US
[patent_app_date] => 2018-06-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 13
[patent_no_of_words] => 10577
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16020517
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/020517 | Method of treating delayed healing of a wound associated with diabetes | Jun 26, 2018 | Issued |
Array
(
[id] => 13827133
[patent_doc_number] => 20190017051
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-17
[patent_title] => OLIGONUCLEOTIDE COMPOSITIONS WITH ENHANCED EFFICIENCY
[patent_app_type] => utility
[patent_app_number] => 16/015009
[patent_app_country] => US
[patent_app_date] => 2018-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22167
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16015009
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/015009 | Oligonucleotide compositions with enhanced efficiency | Jun 20, 2018 | Issued |
Array
(
[id] => 20401245
[patent_doc_number] => 12491205
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-09
[patent_title] => Methods and compositions for controlling cardiac fibrosis and remodeling
[patent_app_type] => utility
[patent_app_number] => 16/623967
[patent_app_country] => US
[patent_app_date] => 2018-06-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 37
[patent_no_of_words] => 15314
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16623967
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/623967 | Methods and compositions for controlling cardiac fibrosis and remodeling | Jun 18, 2018 | Issued |
Array
(
[id] => 13474883
[patent_doc_number] => 20180288984
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-10-11
[patent_title] => METHOD OF PRODUCING INFERTILE FISH AND EGG-PRODUCING AQUATIC ANIMALS AND OF DELIVERING COMPOUNDS INTO EGGS AND EMBRYOS
[patent_app_type] => utility
[patent_app_number] => 16/011631
[patent_app_country] => US
[patent_app_date] => 2018-06-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7199
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16011631
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/011631 | Method of producing infertile fish and egg-producing aquatic animals and of delivering compounds into eggs and embryos | Jun 17, 2018 | Issued |
Array
(
[id] => 17843748
[patent_doc_number] => 11433090
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-06
[patent_title] => mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
[patent_app_type] => utility
[patent_app_number] => 16/621881
[patent_app_country] => US
[patent_app_date] => 2018-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 21
[patent_no_of_words] => 22388
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16621881
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/621881 | mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof | Jun 14, 2018 | Issued |
Array
(
[id] => 16839839
[patent_doc_number] => 20210147851
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-20
[patent_title] => METHODS FOR TREATING MULTIPLE SCLEROSIS USING ANTISENSE OLIGONUCLEOTIDES
[patent_app_type] => utility
[patent_app_number] => 16/622820
[patent_app_country] => US
[patent_app_date] => 2018-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10349
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -34
[patent_words_short_claim] => 154
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16622820
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/622820 | Methods for treating multiple sclerosis using antisense oligonucleotides | Jun 14, 2018 | Issued |
Array
(
[id] => 13508347
[patent_doc_number] => 20180305716
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-10-25
[patent_title] => METHODS AND COMPOSITIONS FOR THE ACTIVATION OF GAMMA-DELTA T-CELLS
[patent_app_type] => utility
[patent_app_number] => 16/008991
[patent_app_country] => US
[patent_app_date] => 2018-06-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21627
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 89
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16008991
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/008991 | Methods and compositions for the activation of gamma-delta T-cells | Jun 13, 2018 | Issued |
Array
(
[id] => 16290340
[patent_doc_number] => 10767177
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-09-08
[patent_title] => Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 16/002034
[patent_app_country] => US
[patent_app_date] => 2018-06-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 56046
[patent_no_of_claims] => 59
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 79
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16002034
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/002034 | Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof | Jun 6, 2018 | Issued |
Array
(
[id] => 15866913
[patent_doc_number] => 20200140860
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-07
[patent_title] => IncRNAs GADLOR 1 AND 2 FOR USE IN TREATING AND PREVENTING CARDIAC REMODELLING
[patent_app_type] => utility
[patent_app_number] => 16/616398
[patent_app_country] => US
[patent_app_date] => 2018-05-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24405
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 92
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16616398
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/616398 | IncRNAs GADLOR 1 and 2 for use in treating and preventing cardiac remodelling | May 29, 2018 | Issued |